CI Stock Recent News
CI LATEST HEADLINES
Cigna (CI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
The Cigna Group (CI) Presents at Barclays 26th Annual Global Healthcare Conference Transcript
Cigna's (CI) strong Evernorth and Cigna Healthcare segments, value enhancing initiatives and a positive 2024 outlook poise it well for growth.
Cigna (CI) currently estimates long-term average annual adjusted EPS growth within 10-14%. It also came up with new solutions to better manage the rising GLP-1 costs and expand behavioral care.
Cigna CEO David Cordani joins 'The Exchange' with CNBC's Bertha Coombs to discuss the company's growth opportunity in services, Cigna's GLP-1 access program, and more.
Cigna Group (CI) said it has taken steps to control the cost and increase coverage of diabetes and weight-loss medicines, which have experienced a boom in demand by those looking to shed pounds.
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Cigna's Evernorth struck agreements with Novo Nordisk and Eli Lilly to limit spending increases for those GLP-1s to a maximum of 15% annually.
Cigna's Evernorth Health Services is launching an outpatient behavioral health practice as health insurers and healthcare providers integrate mental health services with medical care to better address patient needs.
Targeting low-beta stocks can provide a valuable layer of stability for portfolios. After all, defense wins ballgames.